Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:

The board member Philipp von Hugo resigns from Immunovia’s board at his own request

May 6, 2023

LUND (SWEDEN) – Philipp von Hugo, member of the board of directors of Immunovia AB (publ) (“Immunovia” or the “Company”), has at his own request notified his resignation from the Board of Directors of the Company and therefore declines re-election at annual general meeting on 26 May 2023.


Philipp von Hugo, who has served as board member of Immunovia since the annual general meeting in 2022, has on 5 May 2023 at his own request with immediate effect, notified his resignation from his position as board member of Immunovia and consequently declines re-election, at the annual general meeting on 26 May 2023.

The Nomination Committee of the Company has been informed of his decision.

“We thank Philipp for his commitment to the board and wish him the best in his future engagements”, comments the chair of the Board of Directors Carl Borrebaeck.



Carl Borrebaeck

Chair of the Board of Directors

+46 70 821 83 30


Karin Almqvist Liwendahl

Chief Financial Officer

+46 709 11 56 08



Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. The company is headquartered in Lund, Sweden. Immunovia’s shares are listed on Nasdaq Stockholm. For more information please visit

Press release (PDF)